

## Speaker Disclosures

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

### The following financial relationships and/or unlabeled use of drugs or devices have been provided:

**Brett Carol**, *Beth Israel Deaconess Medical Center, Boston, MA*

- Reliant Medical: Consultant
- Bristol Myers Squibb: Institutional Research Support
- Janssen: Consultant

**Steven Dean**, *The Ohio State University Medical Center, Columbus, OH*

- Tactile Medical: Speaker; Scientific Advisory Board

**Sergio Giancesini**, *University of Ferrara, Italy*

- Servier: Speaker Honorarium/Scientific Advisor
- Alfasigma: Speaker Honorarium/Scientific Advisor

**Max Itkin**, *Hospital of the University of Pennsylvania, Philadelphia, PA*

- Guerbet Group: Research Support, Consulting
- Surex: Shareholder
- Umoja: Advisory Board
- Iterious: Research Support

**Stephen J. Kovach**, *University of Pennsylvania Health System, Philadelphia, PA*

- Becton Dickinson: Honorarium
- WL Gore: Honorarium
- Integra Life Sciences: Honorarium
- Checkpoint Surgical: Honorarium

**Barbara Murphy**, *Vanderbilt University Medical Center, Nashville, TN*

- Tactile: Research Support

**Stanley G. Rockson**, *Center for Lymphatic and Venous Disorders, Stanford University School of Medicine, Palo Alto, CA*

- Koya: Consultant, Stock Shareholder
- Fibralign, Inc.: Research Support

**Andrzej Szuba**, *Wroclaw Medical University, Poland*

- Sigvaris: Speaker, Travel Grants
- Thuasne: Advisor, Speaker

- Medi: Speaker, Travel Grants
- Juzo: Speaker

**Joyce Teng**, *Stanford University School of Medicine, Palo Alto, CA*

- Novartis: Consultant and Speaker, Grants
- Pfizer: Grant
- Care Within Reach: Grant
- Novel Pharm: Consultant

### The following speakers have nothing to disclose:

**Kathy Bates**, *LE&RN Spokesperson, Academy Award Winner*

**Francine Blei**, *Professor, NYU Grossman School of Medicine, NY*

**Håkan Brorson**, *Department of Clinical Sciences, Lund University, Malmö, Sweden*

**Jie Deng**, *University of Pennsylvania, Philadelphia, PA*

**Fedor Lurie**, *Jobst Vascular Institute and University of Michigan, Ann Arbor, MI*

**Christine Moffatt**, *Lymphoedema Framework Project, UK*

**William Repicci**, *President and CEO, LE&RN, New York, NY*

**Catherine Seo**, *Lipedema Simplified & Lipedema Project, Boston, MA*

**Dhruv Singhal**, *Beth Israel New England Deaconess Medical Center, Boston, MA*

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: sirolimus, MEK inhibitors, sildenafil, truefill glude, and other medical therapies not currently approved for lymphatic malformations

Earn 5.25 CME Credits Online!

2022 VIRTUAL LYMPHATIC SUMMIT:  
**Lymphatic Disease: The Clinician/Patient Interface  
in State-of-the-Art Diagnosis and Management**  
—FRIDAY, SEPTEMBER 30—  
A forum for LE&RN's Centers of Excellence and the lymphatic disease community.

Centers of Excellence | Stanford SCHOOL OF MEDICINE